

System: ESPI

Report type: current report

Number: 46/2021

Drawn up on: 15 October 2021

---

Subject: Estimated results for Q3 2021

Legal basis: Article 17 (1) of the MAR regulation

Content of the report:

Management Board of Mercator Medical S.A. with its registered seat in Krakow ("Issuer"), based on initial analysis of available financial results of the Issuer and individual entities from the Issuer's Group of Companies, estimates that in the 3<sup>rd</sup> quarter of 2021 the Issuer's Group of Companies obtained the following financial results:

- 1) consolidated sales revenue: 361.8 million PLN, compared to 603.9 million PLN in Q3 2020 and 535.7 million PLN in Q2 2021;
- 2) consolidated EBITDA: 49 million PLN, compared to 390.9 million PLN in Q3 2020 and 118.4 million PLN in Q2 2021,
- 3) consolidated net income: 36.3 million PLN, compared to 355.8 million PLN net income in Q3 2020 and 113.8 million PLN net income in Q2 2021.

As on September 30, 2021, the Issuer's Group had ca. 499.5 million PLN of net cash and other financial assets (investment fund participation units).

The presented values are initial estimates only. The consolidated report for the 3<sup>rd</sup> quarter of 2021 of the Issuer's Group of Companies is being drawn up.

---

First and last name: Wiesław Żyznowski

Position / function: President of the Management Board